US FDA Reorg Emphasizes Office of Therapeutic Biologics and Biosimilars
Final reorganization structure includes new office within OND to coordinate review of biologics and biosimilars applications, as well as new oncology and hematology divisions.
You may also be interested in...
Outgoing commissioner say he has 'extreme confidence' in soon-to-be-acting Commissioner Ned Sharpless and other agency leaders, and expects initiatives advanced during his tenure will be ‘encapsulated and enshrined in regulation and policy’ because they are built on a solid administrative record.
Scott Gottlieb will formally implement a new structure for the Office of the Commissioner just days before he departs from the job. That may be odd timing, but the new structure is in many ways a perfect capstone for Gottlieb’s tenure.
Outgoing FDA commissioner said his direct contact with center directors helped agency advance policies and helped centers solve their problems.